Encephalomyelitis involves inflammation of spinal cord or brain. The various types of the disease include acute disseminated encephalomyelitis, encephalomyelitis disseminate, AntiMOG associated encephalomyelitis, equine encephalomyelitis, myalgic encephalomyelitis, experimental autoimmune encephalomyelitis, progressive encephalomyelitis with rigidity and myoclonus and AIDS related encephalomyelitis. Encephalomyelitis disease is mainly caused by childhood viruses, arboviruses, herpes simplex virus, Epstein-Barr virus, cytomegalovirus and human immunodeficiency virus (HIV). The symptoms associated with the disease includes confusion, headache, weakness, ataxia, seizures, optic neuritis, nausea and vomiting. The disease is treated by corticosteroids, pain killers, mechanical ventilation, anticonvulsants and sedatives. K-PAX Pharmaceuticals, Inc. is in the process of developing KPAX002-3 for the treatment of myalgic encephalomyelitis, the drug candidate is being developed using mitochondrial modulator technology platform. Some of the companies having a pipeline of encephalomyelitis include Baliopharm AG, and Oryzon Genomics.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities, including information about clinical results, designations, collaborations, licencing, grants, technology and others.